- In November 2024, Boston Scientific Corporation announced the completion of its acquisition of Axonics, Inc., a leader in devices for urinary and bowel dysfunction. This acquisition expands Boston Scientific’s Urology portfolio, enhancing its offerings in sacral neuromodulation and tailored treatments for incontinence
- In November 2024, Johnson & Johnson MedTech, announced that the U.S. Food & Drug Administration (FDA) has approved the VARIPULSE Platform for treating drug-resistant paroxysmal Atrial Fibrillation (AFib). This approval positions the company to expand its portfolio of innovative solutions, enhancing its market leadership and offering new therapeutic options to patients with challenging AFib cases
- In October 2024, Boston Scientific Corporation announced FDA approval for the FARAWAVE NAV Ablation Catheter, designed for treating paroxysmal atrial fibrillation (AF), and FDA 510(k) clearance for FARAVIEW Software. These technologies integrate with the FARAPULSE PFA System and OPAL HDx Mapping System, enabling efficient cardiac mapping and therapy with a single catheter
- In May 2024, Biosense Webster, Inc., announced the launch of CARTO 3 System Version 8, the newest iteration of its advanced three-dimensional (3D) heart mapping system used in cardiac ablation procedures. This launch strengthens the company’s position as a pioneer in cardiac technology, offering enhanced capabilities that improve procedural precision and patient outcomes, further solidifying its leadership in the cardiovascular space
- In March 2024, Biosense Webster, Inc., announced the submission of the VARIPULSE Platform for Premarket Approval (PMA) to the U.S. Food & Drug Administration (FDA). This submission marks a significant step in advancing the platform’s approval, which will enable the company to expand its product offerings and strengthen its market presence in the growing atrial fibrillation treatment market
